Targeting Transition Metals for Neuroprotection in Alzheimer's Disease

S. Ayton,A. A. Belaidi,P. Lei,A. I. Bush
DOI: https://doi.org/10.1016/b978-0-12-803690-7.00010-7
2017-01-01
Abstract:Alzheimer’s disease (AD) is a prevalent, devastating, and therapeutically intractable disease of the elderly. Amyloid beta and tau proteins are the main drivers of neurodegeneration in this disease, but drugs targeting these proteins have not been effective in clinical trial so far. The transition metals, iron, copper, and zinc, are also implicated in Alzheimer’s pathogenesis and are alternate drug targets. Here we outline the pathological changes to these transition metals in AD, and discuss the rational and recent attempts to therapeutically target these for disease modification in AD.
What problem does this paper attempt to address?